NervGen Pharma CorpOTCQB:NGENFView on Canadian Exchange
- LAST PRICE1.5920
- TODAY'S CHANGE (%)0.1320 (9.0405%)
- Bid / Lots1.4000/ 50
- Ask / Lots1.8400/ 1
- Open / Previous Close1.5000 / 1.4600
- Day Range
- 52 Week Range
- Volume108,809
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NGENF |
|---|---|---|
| 09:32 ET | 2950 | 1.5 |
| 09:35 ET | 2894 | 1.47 |
| 09:48 ET | 1000 | 1.48 |
| 09:50 ET | 600 | 1.485 |
| 10:18 ET | 1700 | 1.48 |
| 10:40 ET | 170 | 1.492 |
| 10:45 ET | 4000 | 1.49 |
| 10:56 ET | 500 | 1.51 |
| 10:58 ET | 6800 | 1.51 |
| 11:00 ET | 5274 | 1.52 |
| 11:16 ET | 2500 | 1.525 |
| 11:18 ET | 4500 | 1.52 |
| 11:20 ET | 300 | 1.54 |
| 11:30 ET | 3700 | 1.57 |
| 11:45 ET | 450 | 1.63 |
| 12:08 ET | 300 | 1.65 |
| 12:10 ET | 12425 | 1.662 |
| 12:19 ET | 100 | 1.68 |
| 12:35 ET | 4200 | 1.65 |
| 12:37 ET | 1469 | 1.6428 |
| 12:46 ET | 100 | 1.68 |
| 12:48 ET | 2000 | 1.68 |
| 12:55 ET | 100 | 1.67 |
| 01:02 ET | 100 | 1.67 |
| 01:11 ET | 1500 | 1.675 |
| 01:26 ET | 1500 | 1.6727 |
| 01:44 ET | 5700 | 1.65 |
| 01:45 ET | 300 | 1.65 |
| 02:14 ET | 418 | 1.64 |
| 02:36 ET | 1500 | 1.64 |
| 02:43 ET | 5000 | 1.61 |
| 02:45 ET | 5000 | 1.621 |
| 02:48 ET | 100 | 1.62 |
| 02:50 ET | 200 | 1.62 |
| 02:57 ET | 100 | 1.62 |
| 02:59 ET | 700 | 1.62 |
| 03:01 ET | 300 | 1.6 |
| 03:19 ET | 15000 | 1.6 |
| 03:35 ET | 400 | 1.58 |
| 04:00 ET | 3400 | 1.591991 |
Nov 14, 2024
NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates, from 8:31AM ET on Thursday Nov 14, 2024 by Dow Jones
8:31AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 7, 2024
NervGen Pharma to Present at the Stifel 2024 Healthcare Conference, from 8:32AM ET on Thursday Nov 07, 2024 by Dow Jones
8:32AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NervGen Pharma Corp | 146.9M | --- | --- |
Company Information
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.
Contact Information
- Headquarters
- 112-970 Burrard Street, Unit 1290VANCOUVER, BC, Canada V6Z 2R4
- Phone
- 778-731-1711
- Fax
- 604-722-5361
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $146.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.3M |
NervGen Pharma Corp does not pay a dividend. | |
Beta | 1.33 |
EPS | $-0.37 |
Book Value | $-0.03 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
